Researchers at the New Delhi-based National Institute of Immunology (NII), an Autonomous Institute of Department of Biotechnology (DBT), and clinicians at Cancer Institute, Adyar, Chennai have been working together to translate new scientific discoveries into improved care for cancer patients.
Daily Current Affairs Quiz 2021
India’s first indigenous tumour antigen SPAG9 was discovered by Dr Anil Suri in 1998 who is heading the Cancer Research Program at NII.
In a recent development, the SPAG9 antigen has received the trademark ASPAGNIITM. Currently, ASPAGNIITM is being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer.
Immunotherapy is a new approach that exploits the body’s inner capability to put up a fight against cancer.
With this approach, either the immune system is given a boost, or the T cells are “trained’’ to identify recalcitrant cancer cells and kill them.
The ASPAGNIITM is a true example of translational cancer research and the Atmanirbhar Bharat spirit. It will eventually be helpful to patients in India and the world. This will be a real morale boost in affordable, personalised, and indigenous products for cancer treatment.
